BACKGROUND: @entity27791 ( @entity27791 ) is a neuroimaging marker of @entity8267 and has been associated with a high risk for early subsequent major @entity932 ( @entity932 ). Therefore, many experts recommend withholding of antithrombotic medication to @entity1 with @entity27791 . In this study, we sought to investigate the prevalence of @entity27791 and the associated risk of @entity932 in the setting of @entity5275 ( @entity5275 ) for @entity385 . METHODS: We retrospectively searched the medical documentation system of our primary and tertiary care university clinic for all @entity1 with @entity385 that received @entity5275 from 2009 to December 2014. All available imaging data were reviewed in a standardized manner and blinded to any clinical data for the presence of @entity27791 and @entity932 . @entity27791 was defined as linear signal loss along the cerebral cortex on gradient echo T2*-weighted sequences. A @entity64 neurologist, who was blinded to the neuroimaging data, extracted the corresponding clinical data including follow-up information. RESULTS: We identified 298 @entity1 that received @entity5275 and had undergone brain MRI (mean age 67.6    12.6 years, 59.4% male). Cerebral MRI was performed in 116 @entity1 (38.9%) before and in 182 @entity1 (61.1%) after @entity5275 (median time from @entity64 symptom onset to MRI: 1 day; range 0-7 days). Only 3 @entity1 (2 females and 1 male aged 90, 76 and 73 years, respectively) had @entity27791 (1%). All of them had a @entity2500 with a corresponding vessel occlusion. The 76-year-old female @entity1 had extensive @entity27791 and numerous cerebral microbleeds and received another @entity5275 treatment for recurrent @entity2500 8 months after the first event. After both IVTs, she had clinically asymptomatic small @entity932 outside the ischemic @entity1188 and distant from @entity27791 . The 2 other @entity1 had only mild to moderate @entity27791 and did not experience any @entity932 on postthrombolytic imaging. CONCLUSIONS: The prevalence of @entity27791 in a clinical cohort of @entity64 @entity1 that received @entity5275 was low and thus does not appear to pose a substantial risk for symptomatic @entity932 although this may occur in individual @entity1 . However, such analysis also needs to be extended to the very old @entity64 @entity1 in whom @entity5275 is increasingly used.

Cortical Superficial Siderosis and Risk of Bleeding after Thrombolysis for XXXX .

@entity8267 :: ('MESH:D016657', 'Disease') :: ['cerebral amyloid angiopathy'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage', 'ICH'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity5275 :: ('MESH:D015819', 'Disease') :: ['IVT', 'intravenous thrombolysis'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery (MCA) stroke', 'MCA stroke'] @entity27791 :: ('MESH:D012806', 'Disease') :: ['Cortical superficial siderosis', 'CSS'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity385 :: (MESH:D002544,Disease) :: ['Ischemic Stroke']
